➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Boehringer Ingelheim
Express Scripts
Dow
Harvard Business School

Last Updated: August 10, 2020

DrugPatentWatch Database Preview

Patent: 7,071,158

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,071,158
Title:Antioxidant enhancement of therapy for hyperproliferative conditions
Abstract: A method to enhance the cytotoxic activity of an antineoplastic drug comprising administering an effective amount of the antineoplastic drug to a host exhibiting abnormal cell proliferation in combination with an effective cytotoxicity-increasing amount of an antioxidant. The invention also includes a method to decrease the toxicity to an antineoplastic agent or increase the therapeutic index of an antineoplastic agent administered for the treatment of a solid growth of abnormally proliferating cells, comprising administering an antioxidant prior to, with, or following the antineoplastic treatment.
Inventor(s): Chinery; Rebecca (Nashville, TN), Beauchamp; R. Daniel (Nashville, TN), Coffey; Robert J. (Woodside, CA), Medford; Russell M. (Atlanta, GA), Wadzinski; Brian E. (Nashville, TN)
Assignee: Atherogenics, Inc. (Norcross, GA)
Application Number:09/779,086
Patent Claims:see list of patent claims

Details for Patent 7,071,158

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07   Start Trial Atherogenics, Inc. (Norcross, GA) 2017-07-01 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07   Start Trial Atherogenics, Inc. (Norcross, GA) 2017-07-01 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Atherogenics, Inc. (Norcross, GA) 2017-07-01 RX Orphan search
Sigma Tau ONCASPAR pegaspargase VIAL 103411 001 1994-02-01   Start Trial Atherogenics, Inc. (Norcross, GA) 2017-07-01 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Boehringer Ingelheim
Harvard Business School
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.